Distinguished Research Fellow

EDUCATION AND POSITIONS HELD:

• B.S. & M.S., Chemistry, National Tsing Hua University, Taiwan, 1966-1972
• Ph.D., Cell and Developmental Biology, Harvard University, 1973-1977
• Postdoctoral Fellow, Center for Cancer Research, M. I. T., 1977-1980
• Supervisor of Cellular Immunology, Ortho Pharmaceutical Corp., 1980-1981
• Director of Immunology, V. P. of Research, Centocor, Inc., 1981-1985
• Professor of Molecular Virology, Baylor College of Medicine, 1986-1991
• Cofounder 1986, and V.P. of R & D, 1986-1996, Tanox, Inc., Houston
• Professor 1996-2003; Dean 1996-1999; Tsing Hua Professor of Life Science 2003-2006; College of Life Science, National Tsing Hua University
• President, Development Center for Biotechnology, Taipei, 2000-2003
• Distinguished Research Fellow, Genomics Research Center, Academia Sinica, 2006-present

HONORS:

• Foundation for the Advancement of Outstanding Scholarship Award, 1997-2002
• Appointed Science and Technology Advisor of the Executive Yuan, 2002-2006
• Xolair (Chang's anti-IgE invention) approved by FDA, USA, 2003
• Appointed Tsing Hua Professor of Life Science, 2003-2006
• "Honorary Fellow Award" from American College of Allergy, Asthma, and Immunology (ACAAI),2004
• Nature Biotechnology's shortlist of personalities who made the most significant contribution tobiotech in the past 10 years. Nature Biotechnology 24, 291-300, 2006
• Xolair chosen for Prix Galien Award for outstanding innovation in R&D, UK, 2006
• "Honorary Fellow Award" from American Academy of Allergy, Asthma, and Immunology (AAAAI),2007

RESEARCH INTERESTS:

New drug discovery and antibody engineering

The main focus of our group is to develop humanized antibody-based and immunogen-based therapeutics, which target key molecules involved in IgE-mediated allergic pathway. We are also developing new technology platforms for improved antibody engineering. One such program is to develop humanized antibody against CεmX domain in human membrane-bound IgE, for the purpose of controlling IgE-expressing B lymphocytes. CεmX, discovered by our group, is a 52 a.a. domain with a unique sequence. Anti-CεmX, if successfully developed, may be used in combination with an anti-IgE antibody, such as omalizumab (trade name Xolair), which is also derived from Dr. Chang's invention and which is approved for allergic asthma.

SELECTED PUBLICATIONS:

• Chen JB, Wu PC, Hung AF, Chu CY, Tsai TF, Yu HM, Chang HY, Chang TW, 2010, “Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells.”, Journal of immunology, 184(4), 1748-1756. (SCI)
• T. W. Chang* and A. E. Pan, 2008, “Cumulative environmental changes, skewed antigen exposure, and the increase of allergy”, Advances in Immunology, 93, 39-83. (SCI)
• Chang TW, Wu PC, Hsu CL, Hung AF, 2007, “Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.”, Advances in immunology, 93, 63-119. (SCI)
• T. W. Chang* and Y. Y. Shiung, 2006, “Anti-IgE as a mast cell-stabilizing therapeutic agent”, Journal of Allergy and Clinical Immunology, 117(6), 1203-1212. (SCI)